{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:36:44Z","timestamp":1793860604705,"version":"4.6.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013116","name":"merz pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12325-021-01882-9","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:02:55Z","timestamp":1631491375000},"page":"5046-5064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications"],"prefix":"10.1007","volume":"38","author":[{"given":"Warner W.","family":"Carr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wesley","family":"Sublett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"1882_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","volume":"15","author":"J Frevert","year":"2015","unstructured":"Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15:1\u20139.","journal-title":"Drugs R D"},{"key":"1882_CR2","first-page":"33","volume-title":"Botulinum toxin therapy manual for dystonia and spasticity","author":"J Frevert","year":"2016","unstructured":"Frevert J, Dressler D. Clinical relevance of immunoresistance to botulinum therapy. In: Rosales RL, Dressler D, editors. Botulinum toxin therapy manual for dystonia and spasticity. IntechOpen; 2016. p. 33\u201349."},{"key":"1882_CR3","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","volume":"92","author":"P Albrecht","year":"2019","unstructured":"Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92:e48\u201354.","journal-title":"Neurology"},{"key":"1882_CR4","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1111\/jocd.13637","volume":"19","author":"Y Srinoulprasert","year":"2020","unstructured":"Srinoulprasert Y, Wanitphakdeedecha R. Antibody-induced botulinum toxin treatment failure: a review and novel management approach. J Cosmet Dermatol. 2020;19:2491\u20136.","journal-title":"J Cosmet Dermatol"},{"key":"1882_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","volume":"29","author":"M Fabbri","year":"2016","unstructured":"Fabbri M, Leodori G, Fernandes RM, et al. Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis. Neurotox Res. 2016;29:105\u201317.","journal-title":"Neurotox Res"},{"key":"1882_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mdc3.12322","volume":"3","author":"H Hefter","year":"2016","unstructured":"Hefter H, Rosenthal D, Moll M. High botulinum toxin-neutralizing antibody prevalence under long-term cervical dystonia treatment. Mov Disord Clin Pract. 2016;3:500\u20136.","journal-title":"Mov Disord Clin Pract"},{"key":"1882_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.rehab.2019.03.004","volume":"62","author":"L Mathevon","year":"2019","unstructured":"Mathevon L, Declemy A, Laffont I, Perennou D. Immunogenicity induced by botulinum toxin injections for limb spasticity: a systematic review. Ann Phys Rehabil Med. 2019;62:241\u201351.","journal-title":"Ann Phys Rehabil Med"},{"key":"1882_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.clinthera.2007.04.015","volume":"29","author":"SA Yablon","year":"2007","unstructured":"Yablon SA, Brashear A, Gordon MF, et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007;29:683\u201390.","journal-title":"Clin Ther"},{"key":"1882_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","volume":"120","author":"M Naumann","year":"2013","unstructured":"Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2013;120:275\u201390.","journal-title":"J Neural Transm (Vienna)"},{"key":"1882_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","volume":"26","author":"R Benecke","year":"2012","unstructured":"Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012;26:e1-9.","journal-title":"BioDrugs"},{"key":"1882_CR11","doi-asserted-by":"publisher","first-page":"e000646","DOI":"10.1136\/bmjopen-2011-000646","volume":"2","author":"H Hefter","year":"2012","unstructured":"Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H. Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins-a single cohort 4-year follow-up study. BMJ Open. 2012;2:e000646.","journal-title":"BMJ Open."},{"key":"1882_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00702-013-1127-5","volume":"121","author":"H Hefter","year":"2014","unstructured":"Hefter H, Spiess C, Rosenthal D. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. J Neural Transm (Vienna). 2014;121:513\u20139.","journal-title":"J Neural Transm (Vienna)"},{"key":"1882_CR13","doi-asserted-by":"publisher","first-page":"175628641989207","DOI":"10.1177\/1756286419892078","volume":"12","author":"H Hefter","year":"2019","unstructured":"Hefter H, Rosenthal D, Bigalke H, Moll M. Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia. Ther Adv Neurol Disord. 2019;12:1756286419892078.","journal-title":"Ther Adv Neurol Disord"},{"key":"1882_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"P Greene","year":"1994","unstructured":"Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213\u20137.","journal-title":"Mov Disord"},{"key":"1882_CR15","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00192-015-2751-4","volume":"26","author":"N Chohan","year":"2015","unstructured":"Chohan N, Hilton P, Brown K, Dixon L. Efficacy and duration of response to botulinum neurotoxin A (onabotulinumA) as a treatment for detrusor overactivity in women. Int Urogynecol J. 2015;26:1605\u201312.","journal-title":"Int Urogynecol J."},{"key":"1882_CR16","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s00415-019-09681-7","volume":"267","author":"H Hefter","year":"2020","unstructured":"Hefter H, Brauns R, \u00dcrer B, Rosenthal D, Albrecht P. Effective long-term treatment with incobotulinumtoxin (Xeomin\u00ae) without neutralizing antibody induction: a monocentric, cross-sectional study. J Neurol. 2020;267:1340\u20137.","journal-title":"J Neurol"},{"key":"1882_CR17","unstructured":"Botox [package insert]. Dublin, Ireland: Allergan, Inc; 2021."},{"key":"1882_CR18","unstructured":"Xeomin [package insert]. Frankfurt am Main, Germany: Merz Pharmaceuticals GmbH; 2020."},{"key":"1882_CR19","unstructured":"Dysport [package insert]. Wrexham, UK: Ipsen Biopharm Ltd; 2020."},{"key":"1882_CR20","unstructured":"Myobloc [package insert]. Rockville, MD: Solstice Neurosciences, LLC; 2019."},{"key":"1882_CR21","unstructured":"Jeuveau [package insert]. Newport Beach, CA: Evolus; 2019."},{"key":"1882_CR22","unstructured":"Center for Drug Evaluation and Research Administration, US Food and Drug Administration. Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products; 2014. https:\/\/www.fda.gov\/media\/85017\/download. Accessed 27 July 2021."},{"key":"1882_CR23","unstructured":"Center for Drug Evaluation and Research Administration, US Food and Drug Administration. Immunogenicity testing of therapeutic protein products\u2014developing and validating assays for anti-drug antibody detection; 2019. https:\/\/www.fda.gov\/media\/119788\/download. Accessed 27 July 2021."},{"key":"1882_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","volume":"126","author":"SJ van der Veen","year":"2019","unstructured":"van der Veen SJ, van Kuilenburg ABP, Hollak CEM, Kaijen PHP, Voorberg J, Langeveld M. Antibodies against recombinant alpha-galactosidase A in Fabry disease: subclass analysis and impact on response to treatment. Mol Genet Metab. 2019;126:162\u20138.","journal-title":"Mol Genet Metab"},{"key":"1882_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","volume":"13","author":"JR Kalden","year":"2017","unstructured":"Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13:707\u201318.","journal-title":"Nat Rev Rheumatol"},{"key":"1882_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1208\/s12248-016-9998-7","volume":"19","author":"SK Fischer","year":"2017","unstructured":"Fischer SK, Cheu M, Peng K, et al. Specific immune response to phospholipase B-like 2 protein, a host cell impurity in lebrikizumab clinical material. AAPS J. 2017;19:254\u201363.","journal-title":"AAPS J"},{"key":"1882_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/1744666X.2018.1468753","volume":"14","author":"WH Boehncke","year":"2018","unstructured":"Boehncke WH, Brembilla NC. Immunogenicity of biologic therapies: causes and consequences. Expert Rev Clin Immunol. 2018;14:513\u201323.","journal-title":"Expert Rev Clin Immunol"},{"key":"1882_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.mcna.2010.04.003","volume":"94","author":"WJ Pichler","year":"2010","unstructured":"Pichler WJ, Adam J, Daubner B, Gentinetta T, Keller M, Yerly D. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am. 2010;94:645\u201364.","journal-title":"Med Clin North Am"},{"key":"1882_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21:83\u2013100.","journal-title":"Nat Rev Immunol"},{"key":"1882_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/0192623313510987","volume":"42","author":"MW Leach","year":"2014","unstructured":"Leach MW, Rottman JB, Hock MB, Finco D, Rojko JL, Beyer JC. Immunogenicity\/hypersensitivity of biologics. Toxicol Pathol. 2014;42:293\u2013300.","journal-title":"Toxicol Pathol"},{"key":"1882_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00005-012-0189-7","volume":"60","author":"S Sethu","year":"2012","unstructured":"Sethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp. 2012;60:331\u201344.","journal-title":"Arch Immunol Ther Exp"},{"key":"1882_CR32","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","volume":"11","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;11:1951.","journal-title":"Front Immunol"},{"key":"1882_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antib8010021","volume":"8","author":"E Doevendans","year":"2019","unstructured":"Doevendans E, Schellekens H. Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies. 2019;8:21.","journal-title":"Antibodies"},{"key":"1882_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/ACI.0000000000000078","volume":"14","author":"L Faulkner","year":"2014","unstructured":"Faulkner L, Meng X, Park BK, Naisbitt DJ. The importance of hapten-protein complex formation in the development of drug allergy. Curr Opin Allergy Clin Immunol. 2014;14:293\u2013300.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"suppl","key":"1882_CR35","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1097\/00002508-200211001-00004","volume":"18","author":"J Critchfield","year":"2002","unstructured":"Critchfield J. Considering the immune response to botulinum toxin. Clin J Pain. 2002;18(suppl):S133\u201341.","journal-title":"Clin J Pain"},{"key":"1882_CR36","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/jps.22276","volume":"100","author":"SK Singh","year":"2011","unstructured":"Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100:354\u201387.","journal-title":"J Pharm Sci"},{"key":"1882_CR37","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.4049\/jimmunol.1002156","volume":"185","author":"SB Mizel","year":"2010","unstructured":"Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol. 2010;185:5677\u201382.","journal-title":"J Immunol"},{"key":"1882_CR38","volume-title":"Janeway\u2019s immunobiology","author":"K Murphy","year":"2012","unstructured":"Murphy K. Janeway\u2019s immunobiology. 8th ed. New York: Garland Science, Taylor & Francis Group, LLC; 2012.","edition":"8"},{"key":"1882_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1055\/s-2000-12955","volume":"31","author":"J Herrmann","year":"2000","unstructured":"Herrmann J, Mall V, Bigalke H, Geth K, Korinthenberg R, Heinen F. Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy. Neuropediatrics. 2000;31:333\u20134.","journal-title":"Neuropediatrics"},{"key":"1882_CR40","doi-asserted-by":"publisher","first-page":"555","DOI":"10.17219\/acem\/90764","volume":"28","author":"M Przydacz","year":"2019","unstructured":"Przydacz M, Golabek T, Chlosta P. How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA. Adv Clin Exp Med. 2019;28:555\u201367.","journal-title":"Adv Clin Exp Med"},{"key":"1882_CR41","first-page":"225","volume":"27","author":"JJ Ferreira","year":"2012","unstructured":"Ferreira JJ, Bhidayasiri R, Colosimo C, Marti MJ, Zakine B, Maisonobe P. Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol. 2012;27:225\u201330.","journal-title":"Funct Neurol"},{"key":"1882_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","volume":"32","author":"O Lange","year":"2009","unstructured":"Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009;32:213\u20138.","journal-title":"Clin Neuropharmacol"},{"key":"1882_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/toxins12080499","volume":"12","author":"S Samadzadeh","year":"2020","unstructured":"Samadzadeh S, \u00dcrer B, Brauns R, et al. Clinical implications of difference in antigenicity of different botulinum neurotoxin type A preparations: clinical take-home messages from our research pool and literature. Toxins. 2020;12:499.","journal-title":"Toxins"},{"issue":"suppl 3","key":"1882_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.16.3.155","volume":"16","author":"G Schernthaner","year":"1993","unstructured":"Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care. 1993;16(suppl 3):155\u201365.","journal-title":"Diabetes Care"},{"key":"1882_CR45","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neu\u00dfer LP, Rudnicki M, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol. 2018;29:2879\u201389.","journal-title":"J Am Soc Nephrol"},{"key":"1882_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13023-018-0877-4","volume":"13","author":"W Mauhin","year":"2018","unstructured":"Mauhin W, Lidove O, Amelin D, et al. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. Orphanet J Rare Dis. 2018;13:127.","journal-title":"Orphanet J Rare Dis"},{"key":"1882_CR47","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/joim.12647","volume":"282","author":"M Lenders","year":"2017","unstructured":"Lenders M, Oder D, Nowak A, et al. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med. 2017;282:241\u201353.","journal-title":"J Intern Med"},{"key":"1882_CR48","doi-asserted-by":"publisher","first-page":"102398","DOI":"10.1016\/j.autrev.2019.102398","volume":"18","author":"A Rubbert-Roth","year":"2019","unstructured":"Rubbert-Roth A, Szab\u00f3 MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019;18:102398.","journal-title":"Autoimmun Rev."},{"key":"1882_CR49","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA van Schouwenburg","year":"2013","unstructured":"van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:164\u201372.","journal-title":"Nat Rev Rheumatol"},{"key":"1882_CR50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244\u201379.","journal-title":"Pharmacol Ther"},{"key":"1882_CR51","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1097\/MJT.0000000000001076","volume":"27","author":"S Cernea","year":"2020","unstructured":"Cernea S, Raz I. Insulin therapy: future perspectives. Am J Ther. 2020;27:e121\u201332.","journal-title":"Am J Ther"},{"key":"1882_CR52","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/dmrr.714","volume":"23","author":"RP Radermecker","year":"2007","unstructured":"Radermecker RP, Scheen AJ. Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues. Diabetes Metab Res Rev. 2007;23:348\u201355.","journal-title":"Diabetes Metab Res Rev"},{"key":"1882_CR53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/DMP.0b013e318158c5fd","volume":"1","author":"ZF Dembek","year":"2007","unstructured":"Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep. 2007;1:122\u201334.","journal-title":"Disaster Med Public Health Prep"},{"key":"1882_CR54","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.toxicon.2019.07.005","volume":"168","author":"A Kutschenko","year":"2019","unstructured":"Kutschenko A, Bigalke H, Wegner F, Wohlfarth K. The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT\/A products. Toxicon. 2019;168:158\u201363.","journal-title":"Toxicon"},{"key":"1882_CR55","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1073\/pnas.1222139110","volume":"110","author":"DA Benefield","year":"2013","unstructured":"Benefield DA, Dessain SK, Shine N, Ohi MD, Lacy DB. Molecular assembly of botulinum neurotoxin progenitor complexes. Proc Natl Acad Sci U S A. 2013;110:5630\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1882_CR56","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1126\/science.1214270","volume":"335","author":"S Gu","year":"2012","unstructured":"Gu S, Rumpel S, Zhou J, et al. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science. 2012;335:977\u201381.","journal-title":"Science"},{"key":"1882_CR57","doi-asserted-by":"publisher","first-page":"e1003690","DOI":"10.1371\/journal.ppat.1003690","volume":"9","author":"K Lee","year":"2013","unstructured":"Lee K, Gu S, Jin L, et al. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog. 2013;9:e1003690.","journal-title":"PLoS Pathog."},{"issue":"suppl 5","key":"1882_CR58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1468-1331.2001.00035.x","volume":"8","author":"KR Aoki","year":"2001","unstructured":"Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(suppl 5):21\u20139.","journal-title":"Eur J Neurol"},{"key":"1882_CR59","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1586\/erv.13.37","volume":"12","author":"RP Webb","year":"2013","unstructured":"Webb RP, Smith LA. What next for botulism vaccine development? Expert Rev Vaccines. 2013;12:481\u201392.","journal-title":"Expert Rev Vaccines"},{"key":"1882_CR60","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/21645515.2017.1405201","volume":"14","author":"CH Yu","year":"2018","unstructured":"Yu CH, Song DH, Choi JY, et al. A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication. Hum Vaccin Immunother. 2018;14:329\u201336.","journal-title":"Hum Vaccin Immunother"},{"key":"1882_CR61","doi-asserted-by":"publisher","first-page":"7313","DOI":"10.1016\/j.vaccine.2010.08.076","volume":"28","author":"JD Shearer","year":"2010","unstructured":"Shearer JD, Vassar ML, Swiderski W, Metcalfe K, Niemuth N, Henderson I. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A\/B). Vaccine. 2010;28:7313\u20138.","journal-title":"Vaccine"},{"key":"1882_CR62","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.vaccine.2018.02.042","volume":"36","author":"JM Khouri","year":"2018","unstructured":"Khouri JM, Motter RN, Arnon SS. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A\/B, in volunteers with pre-existing botulinum toxoid immunity. Vaccine. 2018;36:2041\u20138.","journal-title":"Vaccine"},{"key":"1882_CR63","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.toxicon.2010.12.019","volume":"57","author":"K-H Eisele","year":"2011","unstructured":"Eisele K-H, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57:555\u201365.","journal-title":"Toxicon"},{"key":"1882_CR64","first-page":"52","volume":"18","author":"M Kerscher","year":"2019","unstructured":"Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, Maas C, Frevert J. IncobotulinumtoxinA: a highly purified and precisely manufactured botulinum neurotoxin type A. J Drugs Dermatol. 2019;18:52\u20137.","journal-title":"J Drugs Dermatol"},{"key":"1882_CR65","first-page":"357","volume":"9","author":"SK Sharma","year":"2000","unstructured":"Sharma SK, Singh BR. Immunological properties of Hn-33 purified from type A Clostridium botulinum. J Nat Toxins. 2000;9:357\u201362.","journal-title":"J Nat Toxins"},{"key":"1882_CR66","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.toxicon.2009.01.017","volume":"53","author":"R Kukreja","year":"2009","unstructured":"Kukreja R, Chang T-W, Cai S, et al. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon. 2009;53:616\u201324.","journal-title":"Toxicon"},{"key":"1882_CR67","first-page":"165","volume":"17","author":"A Sayadmanesh","year":"2013","unstructured":"Sayadmanesh A, Ebrahimi F, Hajizade A, Rostamian M, Keshavarz H. Expression and purification of neurotoxin-associated protein HA-33\/A from Clostridium botulinum and evaluation of its antigenicity. Iran Biomed J. 2013;17:165\u201370.","journal-title":"Iran Biomed J"},{"key":"1882_CR68","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1099\/0022-1317-51-4-286","volume":"51","author":"N Mahmut","year":"2002","unstructured":"Mahmut N, Inoue K, Fujinaga Y, et al. Characterisation of monoclonal antibodies against haemagglutinin associated with Clostridium botulinum type C neurotoxin. J Med Microbiol. 2002;51:286\u201394.","journal-title":"J Med Microbiol"},{"issue":"pt 11","key":"1882_CR69","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1099\/mic.0.28421-0","volume":"151","author":"J-C Lee","year":"2005","unstructured":"Lee J-C, Yokota K, Arimitsu H, et al. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology. 2005;151(pt 11):3739\u201347.","journal-title":"Microbiology"},{"key":"1882_CR70","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.toxicon.2013.06.011","volume":"72","author":"AM Bryant","year":"2013","unstructured":"Bryant AM, Cai S, Singh BR. Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins. Toxicon. 2013;72:126\u201332.","journal-title":"Toxicon"},{"key":"1882_CR71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.toxicon.2014.02.004","volume":"82","author":"L Wang","year":"2014","unstructured":"Wang L, Sun Y, Yang W, Lindo P, Singh BR. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. Toxicon. 2014;82:52\u201360.","journal-title":"Toxicon"},{"key":"1882_CR72","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","volume":"43","author":"J Carruthers","year":"2017","unstructured":"Carruthers J, Solish N, Humphrey S, et al. Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatol Surg. 2017;43:1321\u201331.","journal-title":"Dermatol Surg"},{"key":"1882_CR73","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/DSS.0000000000001903","volume":"45","author":"KR Beer","year":"2019","unstructured":"Beer KR, Shamban AT, Avelar RL, Gross JE, Jonker A. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatol Surg. 2019;45:1381\u201393.","journal-title":"Dermatol Surg"},{"key":"1882_CR74","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","volume":"10","author":"J Frevert","year":"2010","unstructured":"Frevert J. Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae. Drugs R D. 2010;10:67\u201373.","journal-title":"Drugs R D"},{"key":"1882_CR75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00702-011-0719-1","volume":"119","author":"D Dressler","year":"2012","unstructured":"Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae) in an LD50 assay. J Neural Transm. 2012;119:13\u20135.","journal-title":"J Neural Transm"},{"key":"1882_CR76","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.asj.2009.08.004","volume":"29","author":"DD Sutphin","year":"2009","unstructured":"Sutphin DD, Chun J, Hill W, et al. Type A botulinum toxin-induced antibody production: a murine model of antibody response. Aesthet Surg J. 2009;29:414\u20138.","journal-title":"Aesthet Surg J"},{"key":"1882_CR77","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00003495-200767050-00003","volume":"67","author":"WH Jost","year":"2007","unstructured":"Jost WH, Bl\u00fcmel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN\u00ae) in focal dystonia. Drugs. 2007;67:669\u201383.","journal-title":"Drugs"},{"key":"1882_CR78","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14760584.2018.1457443","volume":"17","author":"B Cui","year":"2018","unstructured":"Cui B, Liu X, Fang Y, Zhou P, Zhang Y, Wang Y. Flagellin as a vaccine adjuvant. Expert Rev Vaccines. 2018;17:335\u201349.","journal-title":"Expert Rev Vaccines"},{"key":"1882_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","volume":"145","author":"JD Carruthers","year":"2020","unstructured":"Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145:45\u201358.","journal-title":"Plast Reconstr Surg"},{"key":"1882_CR80","doi-asserted-by":"publisher","first-page":"e2627","DOI":"10.1097\/GOX.0000000000002627","volume":"8","author":"J-Y Park","year":"2020","unstructured":"Park J-Y, Sunga O, Wanitphakdeedecha R, Frevert J. Neurotoxin impurities: a review of threats to efficacy. Plast Reconstr Surg Glob Open. 2020;8:e2627.","journal-title":"Plast Reconstr Surg Glob Open."},{"key":"1882_CR81","unstructured":"Glogau RG, Waugh JM. Preclinical transcutaneous flux experiments using a macromolecule transport system (MTS) peptide for delivery of botulinum toxin type A. In: Poster presented at: 66th Annual Meeting of the American Academy of Dermatology; February 1\u20135, 2008; San Antonio."},{"key":"1882_CR82","doi-asserted-by":"publisher","first-page":"e2109","DOI":"10.1212\/WNL.0000000000009444","volume":"94","author":"U Walter","year":"2020","unstructured":"Walter U, M\u00fchlenhoff C, Benecke R, et al. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. Neurology. 2020;94:e2109\u201320.","journal-title":"Neurology"},{"key":"1882_CR83","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s13555-020-00397-5","volume":"10","author":"R Wanitphakdeedecha","year":"2020","unstructured":"Wanitphakdeedecha R, Kantaviro W, Suphatsathienkul P, et al. Association between secondary botulinum toxin A treatment failure in cosmetic indication and anti-complexing protein antibody production. Dermatol Ther. 2020;10:707\u201320.","journal-title":"Dermatol Ther"},{"key":"1882_CR84","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1442-2042.2008.02016.x","volume":"15","author":"H Schulte-Baukloh","year":"2008","unstructured":"Schulte-Baukloh H, Bigalke H, Miller K, et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol. 2008;15:407\u201315 (discussion 15).","journal-title":"Int J Urol."},{"key":"1882_CR85","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000081463","volume":"52","author":"D Dressler","year":"2004","unstructured":"Dressler D, Bigalke H. Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol. 2004;52:132\u20135.","journal-title":"Eur Neurol"},{"key":"1882_CR86","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ana.20098","volume":"55","author":"J Herrmann","year":"2004","unstructured":"Herrmann J, Geth K, Mall V, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol. 2004;55:732\u20135.","journal-title":"Ann Neurol"},{"key":"1882_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab058","author":"E Rahman","year":"2021","unstructured":"Rahman E, Alhitmi HK, Mosahebi A. Immunogenicity to botulinum toxin type A: a systematic review with meta-analysis across therapeutic indications. Aesthet Surg J. 2021. https:\/\/doi.org\/10.1093\/asj\/sjab058.","journal-title":"Aesthet Surg J."},{"key":"1882_CR88","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23:1353\u201360.","journal-title":"Mov Disord"},{"key":"1882_CR89","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","volume":"116","author":"K M\u00fcller","year":"2009","unstructured":"M\u00fcller K, Mix E, Adib Saberi F, Dressler D, Benecke R. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm. 2009;116:579\u201385.","journal-title":"J Neural Transm"},{"issue":"suppl 1","key":"1882_CR90","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1093\/asj\/sjx010","volume":"37","author":"JL Cohen","year":"2017","unstructured":"Cohen JL, Scuderi N. Safety and patient satisfaction of abobotulinumtoxinA for aesthetic use: a systematic review. Aesthet Surg J. 2017;37(suppl 1):S32\u201344.","journal-title":"Aesthet Surg J"},{"issue":"suppl 4","key":"1882_CR91","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1111\/j.1524-4725.2010.01710.x","volume":"36","author":"D Dressler","year":"2010","unstructured":"Dressler D, Wohlfahrt K, Meyer-Rogge E, Wiest L, Bigalke H. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg. 2010;36(suppl 4):2182\u20137.","journal-title":"Dermatol Surg"},{"key":"1882_CR92","first-page":"11","volume":"7","author":"S Torres","year":"2014","unstructured":"Torres S, Hamilton M, Sanches E, Starovatova P, Gubanova E, Reshetnikova T. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol. 2014;7:11\u20137.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"suppl 3","key":"1882_CR93","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1097\/DSS.0000000000001409","volume":"43","author":"WP Coleman III","year":"2017","unstructured":"Coleman WP III, Sattler G, Weissenberger P, Hast MA, Hanschmann A. Safety of incobotulinumtoxinA in the treatment of facial lines: results from a pooled analysis of randomized, prospective, controlled clinical studies. Dermatol Surg. 2017;43(suppl 3):S293\u2013303.","journal-title":"Dermatol Surg"},{"key":"1882_CR94","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","volume":"82","author":"V Bertucci","year":"2020","unstructured":"Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82:838\u201345.","journal-title":"J Am Acad Dermatol"},{"issue":"pt A","key":"1882_CR95","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.toxicon.2015.06.003","volume":"107","author":"MZ Atassi","year":"2015","unstructured":"Atassi MZ. Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions. Toxicon. 2015;107(pt A):50\u20138.","journal-title":"Toxicon"},{"key":"1882_CR96","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.molimm.2006.03.011","volume":"44","author":"BZ Dolimbek","year":"2007","unstructured":"Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT\/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT\/A. Mol Immunol. 2007;44:1029\u201341.","journal-title":"Mol Immunol"},{"key":"1882_CR97","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/toxins11090491","volume":"11","author":"S Bellows","year":"2019","unstructured":"Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins. 2019;11:491.","journal-title":"Toxins"},{"key":"1882_CR98","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/nau.23354","volume":"37","author":"J Ni","year":"2018","unstructured":"Ni J, Wang X, Cao N, Si J, Gu B. Is repeat botulinum toxin A injection valuable for neurogenic detrusor overactivity\u2014a systematic review and meta-analysis. Neurourol Urodyn. 2018;37:542\u201353.","journal-title":"Neurourol Urodyn"},{"key":"1882_CR99","unstructured":"European Medicines Agency. Guideline on Immunogenicity Assessment of Therapeutic Proteins; 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed 27 July 2021."},{"key":"1882_CR100","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","volume":"118","author":"B Wabbels","year":"2011","unstructured":"Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenk\u00e4mper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm. 2011;118:233\u20139.","journal-title":"J Neural Transm"},{"key":"1882_CR101","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/WNO.0000000000000110","volume":"34","author":"J Saad","year":"2014","unstructured":"Saad J, Gourdeau A. A direct comparison of onabotulinumtoxina (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique. J Neuroophthalmol. 2014;34:233\u20136.","journal-title":"J Neuroophthalmol"},{"key":"1882_CR102","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenk\u00e4mper","year":"2006","unstructured":"Roggenk\u00e4mper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303\u201312.","journal-title":"J Neural Transm"},{"key":"1882_CR103","first-page":"CD003633","volume":"12","author":"M Castel\u00e3o","year":"2017","unstructured":"Castel\u00e3o M, Marques RE, Duarte GS, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2017;12:CD003633.","journal-title":"Cochrane Database Syst Rev."},{"key":"1882_CR104","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2340\/16501977-1009","volume":"44","author":"A Santamato","year":"2012","unstructured":"Santamato A, Ranieri M, Panza F, et al. Effectiveness of switching therapy from complexing protein-containing botulinum toxin type A to a formulation with low immunogenicity in spasticity after stroke: a case report. J Rehabil Med. 2012;44:795\u20137.","journal-title":"J Rehabil Med"},{"key":"1882_CR105","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2340\/16501977-1895","volume":"47","author":"DG Grosset","year":"2015","unstructured":"Grosset DG, Tyrrell EG, Grosset KA. Switch from abobotulinumtoxinA (Dysport\u00ae) to incobotulinumtoxinA (Xeomin\u00ae) botulinum toxin formulation: a review of 257 cases. J Rehabil Med. 2015;47:183\u20136.","journal-title":"J Rehabil Med"},{"key":"1882_CR106","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00702-018-1911-3","volume":"125","author":"D Dressler","year":"2018","unstructured":"Dressler D, Pan L, Adib SF. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity. J Neural Transm. 2018;125:1481\u20136.","journal-title":"J Neural Transm"},{"key":"1882_CR107","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1212\/01.wnl.0000287087.99612.e5","volume":"70","author":"G Kranz","year":"2008","unstructured":"Kranz G, Sycha T, Voller B, Kranz GS, Schnider P, Auff E. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008;70:133\u20136.","journal-title":"Neurology"},{"key":"1882_CR108","doi-asserted-by":"publisher","first-page":"636590","DOI":"10.3389\/fneur.2021.636590","volume":"12","author":"H Hefter","year":"2021","unstructured":"Hefter H, Hartmann CJ, Kahlen U, Samadzadeh S, Rosenthal D, Moll M. Clinical improvement after treatment with incobotulinumtoxinA (XEOMIN\u00ae) in patients with cervical dystonia resistant to botulinum toxin preparations containing complexing proteins. Front Neurol. 2021;12:636590.","journal-title":"Front Neurol."},{"key":"1882_CR109","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/lary.27709","volume":"129","author":"JR Shinn","year":"2019","unstructured":"Shinn JR, Nwabueze NN, Patel P, Norton C, Ries WR, Stephan SJ. Contemporary review and case report of botulinum resistance in facial synkinesis. Laryngoscope. 2019;129:2269\u201373.","journal-title":"Laryngoscope"},{"key":"1882_CR110","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","volume":"67","author":"J Jankovic","year":"2006","unstructured":"Jankovic J, Hunter C, Dolimbek BZ, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67:2233\u20135.","journal-title":"Neurology"},{"issue":"pt A","key":"1882_CR111","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.toxicon.2015.08.001","volume":"107","author":"AR Bentivoglio","year":"2015","unstructured":"Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015;107(pt A):77\u201384.","journal-title":"Toxicon"},{"key":"1882_CR112","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/mds.20531","volume":"20","author":"SA Factor","year":"2005","unstructured":"Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord. 2005;20:1152\u201360.","journal-title":"Mov Disord"},{"key":"1882_CR113","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3390\/toxins12110677","volume":"12","author":"H Hefter","year":"2020","unstructured":"Hefter H, Samadzadeh S, Moll M. Transient improvement after switch to low doses of rimabotulinumtoxinB in patients resistant to abobotulinumtoxinA. Toxins. 2020;12:677.","journal-title":"Toxins"},{"key":"1882_CR114","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00415-003-1129-6","volume":"250","author":"D Dressler","year":"2003","unstructured":"Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol. 2003;250:967\u20139.","journal-title":"J Neurol"},{"key":"1882_CR115","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/mds.20073","volume":"19","author":"B Voller","year":"2004","unstructured":"Voller B, Moraru E, Auff E, et al. Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A. Mov Disord. 2004;19:943\u20137.","journal-title":"Mov Disord"},{"key":"1882_CR116","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200\u201335.","journal-title":"Pharmacol Rev"},{"key":"1882_CR117","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1080\/09638280701568296","volume":"29","author":"D Dressler","year":"2007","unstructured":"Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29:1761\u20138.","journal-title":"Disabil Rehabil"},{"key":"1882_CR118","doi-asserted-by":"publisher","first-page":"7","DOI":"10.11138\/FNeur\/2018.33.1.007","volume":"33","author":"A Ferrari","year":"2018","unstructured":"Ferrari A, Manca M, Tugnoli V, Alberto L. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. Funct Neurol. 2018;33:7\u201318.","journal-title":"Funct Neurol"},{"key":"1882_CR119","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/DSS.0000000000001277","volume":"44","author":"JS Dover","year":"2018","unstructured":"Dover JS, Monheit G, Greener M, Pickett A. Botulinum toxin in aesthetic medicine: myths and realities. Dermatol Surg. 2018;44:249\u201360.","journal-title":"Dermatol Surg"},{"key":"1882_CR120","doi-asserted-by":"publisher","first-page":"35617","DOI":"10.1074\/jbc.M113.521179","volume":"288","author":"S Amatsu","year":"2013","unstructured":"Amatsu S, Sugawara Y, Matsumura T, Kitadokoro K, Fujinaga Y. Crystal structure of Clostridium botulinum whole hemagglutinin reveals a huge triskelion-shaped molecular complex. J Biol Chem. 2013;288:35617\u201325.","journal-title":"J Biol Chem"},{"key":"1882_CR121","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186\u20138.","journal-title":"Neurology"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01882-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01882-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01882-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T06:21:06Z","timestamp":1632810066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01882-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":121,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1882"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01882-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}